Aptuit to expand API capacity due to increased demand for integrated development

Opens 1600L/1000L reactor stream at Oxford, UK and increases API capacity at Verona, Italy

Aptuit has increased its global capacity for manufacturing active pharmaceutical ingredients (API) to meet increased demand for both APIs and its integrated and comprehensive candidate-to-IND development solution.

Chief Executive Jonathan Goldman said customer demand for the company's integrated, candidate-to-IND solutions has increased over 300% on an annual basis. As a result, the company has opened a 1600L/1000L reactor stream at its API facility in Oxford, UK and has increased the throughput of its 400L reactors at its Pharma R&D centre of excellence in Verona, Italy.

Goldman explained that Aptuit's strategy will allow increased throughput of integrated development programmes, as well as deliver standalone API at 40–120kg batch scale for early- to mid-stage clinical trials.

'There is a gap in the market for high quality API at this scale, and Aptuit is delighted to serve this need,' he said.

Companies